Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $17,340.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00. Following the transaction, the chief executive officer now directly owns 14,619,350 shares in the company, valued at approximately $126,749,764.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Performance

Shares of Zynex stock opened at $9.01 on Friday. The stock has a market cap of $286.97 million, a price-to-earnings ratio of 60.07 and a beta of 0.53. The firm’s 50-day moving average is $8.18 and its 200 day moving average is $8.98. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. Zynex’s revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. Sell-side analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ZYXI shares. Royal Bank of Canada dropped their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright boosted their target price on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th.

Hedge Funds Weigh In On Zynex

Hedge funds have recently bought and sold shares of the company. Gladius Capital Management LP boosted its stake in Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in Zynex during the 1st quarter valued at about $137,000. Investment Partners Asset Management Inc. bought a new position in Zynex during the 3rd quarter valued at about $96,000. Hsbc Holdings PLC bought a new position in Zynex during the 2nd quarter valued at about $113,000. Finally, Quest Partners LLC lifted its stake in Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after acquiring an additional 11,195 shares during the period. Institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.